Pharma Business - December 9, 2025
Xinnate receives FDA IND approval
The US Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for TCP-25, a novel topical immunomodulatory peptide being developed for the treatment of Epidermolysis Bullosa (EB).
New Market - December 9, 2025
Cinclus Pharma’s linaprazan glurate earns China’s National Reimbursement Listing
Cinclus Pharma Holding's drug linaprazan glurate has been included in China’s 2025 National Reimbursement Drug List (NRDL) for the treatment of gastroesophageal reflux disease (GERD).
Pharma Business - December 3, 2025
Lundbeck does not intend to make an offer for Avadel
After a comprehensive assessment of the latest process dynamics, Lundbeck has concluded that increasing the purchase price set out in its non-binding proposal announced on November 14 would not meet its strategic or financial criteria for value creation.
Pharma Award - December 2, 2025
NADMED launches USD 30,000 award
The company has announced the launch of the NADMED Award 2026, a global initiative designed to empower scientific discovery in redox biology and accelerate innovation across medicine, life sciences, and biotechnology.
CDMO - December 1, 2025
NorthX Biologics and Mendus complete GMP manufacturing certification
The GMP manufacturing certification concerns Mendus’ lead cell therapy product, vididencel.
Global report - November 24, 2025
AstraZeneca plans USD 2 billion manufacturing investment in Maryland
This is the fourth major US manufacturing investment announced this year.
